Time (Months)|^|Biological Activity (Binding ELISA)|^|CEX-HPLC|^|CEX-HPLC|^|CGE (non-reducing)|^|CGE (non-reducing)|^|CGE (non-reducing)|^|CGE (reducing)|^|CGE (reducing)|^|CGE (reducing)|^|Endotoxin|^|Osmolarity|^|Peptide Mapping|^|SE-HPLC|^|SE-HPLC|^|Sterility|^|Subvisible Particles|^|Subvisible Particles|^|Subvisible Particles|^|UV Spectroscopy|^|iCE|^|iCE|^|iCE|^|pH
Time (Months)|^|Relative Potency|^|Anti-BCMA mAb|^|Anti-BCMA/Anti-CD3 Bispecific Clip|^|Fragments|^|Intact IgG|^|Other|^|Fragments|^|Heavy Chain + Light Chain|^|Other|^|Endotoxin|^|Osmolarity|^|Identity (Peptide Profile)|^|HMMS|^|Monomer|^|Sterility|^|Subvisible Particles|^|Subvisible Particles >= 10µm|^|Subvisible Particles >= 25µm|^|Protein Concentration|^|Acidic Species|^|Basic Species|^|Main Species|^|pH
Clinical Acceptance Criteria|^|50 - 150% potency relative to reference material|^|<= 3.0% anti BCMA parent mAb|^|<= 5.0% Bispecific mAb Clip|^|<= 10.0% fragments|^|>= 90.0% IgG|^|Report Results|^|-|^|-|^|-|^|<= 10 EU/mg|^|Report Results|^|Comparable to Reference|^|<= 5.0% HMMS|^|>= 90.0% monomer|^|No growth detected|^|Meets compendial requirements|^|Report Results|^|Report Results|^|2.0 +/- 0.2 mg/mL|^|Report Results|^|Report Results|^|Report Results|^|5.8 +/- 0.5
0|^|92|^|NMT 0.1|^|0.4|^|0.8|^|99.2|^|NMT 0.3|^|0.9|^|99.1|^|NMT 0.3|^|NMT 1|^|310|^|Comparable to Reference|^|0.4|^|99.6|^|No growth detected|^|Meets compendial requirements|^|5|^|<1|^|2.0|^|38.7|^|14.7|^|46.6|^|5.7
1|^|97|^|0.2|^|0.6|^|0.5|^|99.5|^|NMT 0.3|^|0.9|^|99.1|^|NMT 0.3|^|NR|^|NR|^|NR|^|0.3|^|99.6|^|NR|^|NR|^|NR|^|NR|^|2.0|^|40.4|^|14.7|^|44.9|^|5.8

